Loading clinical trials...
Loading clinical trials...
Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alberta Health services
NCT06638931 · Urachal Cancer, Parathyroid Carcinoma, and more
NCT07447089 · Thyroid Neoplasms, Neoplasm, and more
NCT06220656 · Thyroid Nodule, Thyroid Neoplasms, and more
NCT07033572 · Thyroid Neoplasms, Carcinoma, Papillary
NCT07010380 · Thyroid Neoplasms, Hyperparathyroidism, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions